CRS-207

BIOLOGICAL9 trials

Sponsors

Aduro Biotech, Inc., Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions

2nd-line, 3rd-line and Greater Metastatic Pancreatic CancerEsophageal AdenocarcinomaGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaMalignant Pleural MesotheliomaMetastatic Pancreatic AdenocarcinomaMetastatic Pancreatic CancerPancreatic Cancer

Phase 1

Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer

TerminatedNCT02575807

Aduro Biotech, Inc.Platinum-resistant Fallopian Cancer, Platinum-resistant Ovarian Cancer, Platinum-resistant Peritoneal Cancer

Start: 2016-03-08End: 2018-05-08Updated: 2019-04-04

Phase 2

Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer

CompletedNCT01417000

Aduro Biotech, Inc.Metastatic Pancreatic Cancer

Start: 2011-09-21End: 2017-02-10Updated: 2018-05-08

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

CompletedNCT02004262

Aduro Biotech, Inc.2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer

Start: 2014-02-05End: 2016-08-23Updated: 2018-06-04

GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab

CompletedNCT02243371

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPreviously Treated Metastatic Adenocarcinoma of the Pancreas

Start: 2015-01-02End: 2017-07-21Updated: 2021-04-06

Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer

CompletedNCT03006302

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMetastatic Pancreatic Adenocarcinoma

Start: 2018-01-31End: 2024-08-05Updated: 2024-10-08

Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers

TerminatedNCT03122548

Aduro Biotech, Inc.Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

Start: 2017-08-14End: 2018-01-31Updated: 2019-04-04

Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)

TerminatedNCT03175172

Aduro Biotech, Inc.Malignant Pleural Mesothelioma

Start: 2017-05-31End: 2018-01-31Updated: 2019-04-04

Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer

CompletedNCT03190265

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPancreatic Cancer

Start: 2017-12-14End: 2023-08-23Updated: 2024-08-07

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Active, not recruitingNCT05014776

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPancreatic Cancer

Start: 2022-08-22End: 2026-04-03Updated: 2026-02-24

Related Papers

Data from A Randomized Phase II Study: CRS207/GVAX plus Anti–PD‐1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC

2026-03-04

A randomized phase II study: CRS207/GVAX plus anti-PD1 and anti-CTLA4 recruits mesothelin- and mKRAS-specific T cells into PDAC.

2026-01-12

Abstract PR-08: Reprogramming and selective recruitment of distinct neutrophil subpopulations restrain cancer metastasis

Cancer Research2024-09-15

Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).

2019-05-24199 citations

A phase II single-arm study of CRS-207 with pembrolizumab (pembro) in previously treated malignant pleural mesothelioma (MPM).

Journal of Clinical Oncology2019-03-1015 citations

T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.

2018-07-12191 citations

A phase 2 trial of CRS-207 and pembrolizumab in adults with recurrence of metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinomas.

Journal of Clinical Oncology2018-02-011 citations

Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).

Journal of Clinical Oncology2017-02-0145 citations

Randomized phase 2 study of the safety, efficacy, and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR).

Journal of Clinical Oncology2016-05-203 citations

Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR).

Journal of Clinical Oncology2016-02-0113 citations

Clinical and immune characteristics of rapid dropout and long-term survival in a phase II safety and efficacy study of combination CRS-207/GVAX immunotherapy in pancreatic cancer.

Journal of Clinical Oncology2016-02-013 citations

Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR).

Journal of Clinical Oncology2015-05-209 citations

Phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer: Clinical update on long term survival and biomarker correlates to overall survival.

Journal of Clinical Oncology2015-01-2011 citations

A phase IIb, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).

Journal of Clinical Oncology2015-01-202 citations

A phase 2b, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).

Journal of Clinical Oncology2014-05-20

A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results.

Journal of Clinical Oncology2014-01-2030 citations

A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone...

Columbia Academic Commons (Columbia University)2014-01-01